Excerpts

Only the treated male mice showed a trend ( p = 0.12) to improved performance as indicated by an increase in spontaneous alteration rate.

Ogg1-KO mice fed LFD showed a trend toward lower lean body mass ( p = 0.1218, Supplementary Figure S1B ) and higher fat mass ( p = 0.1231, Supplementary Figure S1C ) compared to WT/LFD mice although neither difference was significant.

In multivariable Cox regression analysis adjusted for age, tumor size, lymph node status, histologic grade, and Ki-67, high AMPKβ protein expression was significantly associated with poorer DFS (HR, 2.932; 95% CI, 1.009–8.519; p = 0.048), while only a nonsignificant trend toward poorer DDFS was observed (HR, 2.645; 95% CI, 0.765–9.139; p = 0.124) in patients with early TNBC ( Supplementary Table S2 ).

Specifically, CA3 was higher in the cold–wet (↓CI/↑RAP) group than in warm–dry (↑CI/↓RAP; p = 0.034) and showed a trend toward being higher than warm–wet (↑CI/↑RAP; p = 0.128; Figure 2 a).

Using multicolor FACS analysis, we showed that there is a positive trend of correlation (correlation coefficient = 0.80, p = 0.13 on cycle 1 day 8; correlation coefficient = 0.50, p = 0.45 on cycle 1 day 15) between the early granulocyte (CD45 + CD66b + ) population relative to progression free survival (PFS) (months) over cycle 1 of treatment ( Supplementary Figure S2c ).

Although the high APOC2 expression group showed a trend toward lower survival compared to the low expression group, this difference was not statistically significant (log-rank test, p = 0.13) ( Figure 4 B).

Since these SNPs were close to significance, the haplotype was considered, but even combined together, they were not correlated with the grade of side effect ( p = 0.13).

In A2780 cell line statistically significant decreased expression of PTPRK was observed after 24 h, 48 h and 72 h incubation ( p < 0.05), with the exception of 10 ng/mL after 48 h incubation where downregulation was close to significance ( p = 0.13) ( Figure 4 B). 2.5.

However, we did find an almost significant difference for TrpN, with an increase in children with moderate impairment (389.13 vs. 528.14; p = 0.13).

A concentration of 50 μM showed a trend towards increased LDH release, although the difference to untreated control cells remained statistically non-significant ( p = 0.13).

Lung weight showed a decreasing trend in the DOXO-only group compared to the control group ( p = 0.13).

In a different randomized trial in the adjuvant setting, AE37 and GP2, two other HER2 derived peptide vaccines were investigated in a four-arm, prospective, randomized, single-blinded, multi-center phase II trial; the AE37 arm showed no difference in DFS overall; however, subgroup analyses showed a trend towards benefit in advanced stage ( p = 0.132, HR 0.573 CI 0.275–1.193), HER2 under-expression ( p = 0.181, HR 0.756 CI 0.499–1.145), and triple-negative breast cancer ( p = 0.266, HR 0.443 CI 0.114–1.717).

This correlation trend was also observed for the functional BCL-2 BH3 profile and CHOP response, in which a high BAD response showed a trend towards high CHOP IC 50 values ( r = 0.595; p = 0.1323) ( Figure 3 E).

Also, LV mass showed a trend towards an increase in the DEB1 subgroup compared to DEB2 ( p = 0.134, Figure 1 E).

Socioeconomic and social factors (k = 4) [ 79 , 80 , 81 , 82 ] showed a positive trend ( p = 0.139), but no statistically significant association was observed.

No significant difference in toughness was evidenced between the two groups of animals, even if the data were close to the limit of significance ( Figure 2 E; −33%, p = 0.14).

Of interest, after 24 h the four individuals with highest LLS showed a trend towards lower IL-10 plasma concentrations (lowest LLS 4.02 (2.18–7.13) pg/mL vs. highest LLS 1.80 (0.91–2.48) pg/mL, p = 0.14). 2.5.2.

The low dosage (Low) group showed a trend of inhibitory effect on paw swelling when compared with the model group ( p = 0.14), as shown in Figure 1 B,C.

The area under the curve measurements for these conditions show a nonsignificant trend toward increased migration ( Figure 5 B; p = 0.144).

At day 10, the difference in collagen III expression was nearly significant ( p = 0.145), with FBs expressing 31.33 ± 1.62%, cocultures 40.60 ± 2.86%, and ECs 44.92 ± 7.92%.

SLC16A3 also showed a trend toward an inverse correlation with brain pH in controls (r = −0.49, p = 0.15) and a significant inverse correlation in SCZ (r = −0.65, p = 0.04), but not in BD (r = +0.49, p = 0.15).

10 μM NPA-, 50 μM NPA-, and 100 μM NPA-treated gametophytes exhibited a median RMR comparable to the DMSO solvent mock, although the 100 μM NPA-treated group was trending toward significance ( p = 0.15) in comparison to either of the lower concentrations of NPA ( p > 0.99) ( Figure 6 k).

Non-HSCT GATA2-deficient patients showed a trend toward increased relative abundance of Proteobacteria compared with HD and post-HSCT patients ( p = 0.15 and p = 0.73, respectively; Figure 2 A,B).

Statistical significance was defined as a p -value of < 0.05, with a tendency toward significance defined as 0.05 ≤ p < 0.15.

Mocetinostat showed a decreasing trend in the level of STAT3 protein in LV of treated CHF compared to untreated CHF animals ( p = 0.15).